Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

NCT02371980 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1106

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Vortioxetine
DRUG: Placebo

Sponsor

Takeda